Our cohort has the distinct advantage of having a rich longitudinal clinical dataset as well as measures of mosquito exposure both prior to and following the blood draw, enabling evaluation of both the determinants of the CD4 response and correlates of prospective protection from both parasitemia and clinical malaria. The gene discussed is CD4; the disease is malaria.